Trials / Unknown
UnknownNCT05199649
Correlation Between the Efficacy of Neoadjuvant Chemotherapy Combined With Immunotherapy of Operable Thoracic Esophageal Squamous Cell Carcinoma and the Metabolites of Intestinal Flora
- Status
- Unknown
- Phase
- N/A
- Study type
- Interventional
- Enrollment
- 30 (estimated)
- Sponsor
- The First Affiliated Hospital of Soochow University · Academic / Other
- Sex
- All
- Age
- 18 Years – 75 Years
- Healthy volunteers
- Not accepted
Summary
This study collects stool, blood, and tumor tissue samples from patients with locally advanced esophageal cancer after receiving Sintilimab and chemotherapy to explore the efficacy and intestinal microbes of chemotherapy combined with neoadjuvant immunotherapy for locally advanced operable thoracic esophageal squamous cell carcinoma The main purpose is the relationship between its metabolites, and it will also explore the changes of intestinal flora diversity and metabolites before and after esophageal squamous cell carcinoma chemotherapy combined with immune neoadjuvant therapy
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | SintilimabCombined With Chemotherapy | Sintilimab and chemotherapy are carried out at the same time for every 3 weeks |
Timeline
- Start date
- 2021-12-01
- Primary completion
- 2023-06-01
- Completion
- 2023-06-01
- First posted
- 2022-01-20
- Last updated
- 2022-01-20
Locations
1 site across 1 country: China
Source: ClinicalTrials.gov record NCT05199649. Inclusion in this directory is not an endorsement.